Nucleic acid (NA)-sensing Toll-like receptors (TLRs) respond to DNA/RNA derived from pathogens and dead cells. Structural studies have revealed a variety of molecular mechanisms by which TLRs sense NAs. Double-stranded RNA and single-stranded DNA directly bind to TLR3 and TLR9, respectively, whereas TLR7 and TLR8 bind to nucleosides and oligoribonucleotides derived from RNAs. Activation of ligand-bound TLRs is influenced by the functional status of TLRs. Proteolytic cleavage of NA-sensing TLRs enables ligand-dependent TLR dimerization. Trafficking of ligandactivated TLRs in endosomal and lysosomal compartments is requisite for production of type I interferons. Activation of NA-sensing TLRs is required for the control of viruses such as herpes simplex virus and endogenous retroviruses. On the other hand, excessive activation of NA-sensing TLRs drives disease progression in a variety of inflammatory diseases including systemic lupus erythematosus, heart failure, arthritis and non-alcoholic steatohepatitis. NA-sensing TLRs are targets for therapeutic intervention in these diseases. We here focus on our recent progresses in our understanding of NA-sensing TLRs.
Introduction
Toll-like receptors (TLRs) serve as the first line of defense against pathogens by sensing a variety of pathogen components. TLRs are type I transmembrane proteins expressed on the cell surface and within endosomal compartments in a variety of innate immune cells. Extracellular domains consist of a protein motif called leucine-rich repeats (LRRs), which directly interact with TLR ligands. TLRs respond to extracellular or endocytosed TLR ligands. Autophagy enables TLR responses to cytoplasmic TLR ligands. Downstream signaling pathways activate transcription factors such as NF-κBs and interferon regulatory factors (IRFs), leading to production of pro-inflammatory cytokines and type I interferons (type I IFNs).
Nucleic acids (NAs) are among the best-studied TLR ligands. TLR3 and TLR7/TLR8 respond to double-stranded RNA (dsRNA) and single-stranded RNA (ssRNA), respectively (1) (2) (3) . However, the structures of TLR7 and TLR8 raise a possibility that they respond to nucleosides (4) (5) (6) . TLR9 responds to single-stranded DNA (ssDNA) (7, 8) . Pathogenderived NAs are preferentially sensed by TLRs. TLR9, e.g., shows stronger responses to bacterial unmethylated CpG motif than the methylated CpG motif commonly found in the mammalian genome. TLR3 responds to dsRNA longer than 40 bp (9) . Despite this discrimination between self and pathogen, recent studies show TLR responses to self-NAs in disease states such as autoimmune diseases. NA-sensing TLRs are likely to drive disease progression in a variety of noninfectious, inflammatory diseases.
Here we discuss recent progresses in our understanding of NA sensing by TLRs, mechanisms controlling TLR responses and diseases caused by NA-sensing TLRs.
ssDNA sensing by TLR9
The structure of TLR9 complexed with ssDNA fragments demonstrates the direct interaction between TLR9 and ssDNA fragments ( Fig. 1) (7) . CpG, the motif indispensable for TLR9 activation (10) , is required for interaction between ssDNA fragments and the N-terminal LRR cluster of the extracellular domain of TLR9. The C-terminal LRR cluster in the extracellular domain has another binding site for ssDNA. These two binding sites enable ligand-mediated dimerization of TLR9, leading to activation of downstream signaling pathways.
Chromosomal and mitochondrial DNA is dsDNA, which needs to be digested into short ssDNA fragment before binding to TLR9. DNase II is the lysosomal DNase required for DNA processing for DNA sensing by TLR9. Dnase2a −/− mice suffer from systemic inflammatory diseases (11) , which are dependent on cytoplasmic DNA sensors such as cGAS-STING (cyclic GMP-AMP synthase-stimulator of interferon genes) and AIM2 (absent in melanoma 2) (12-14), but not on lysosomal TLR9 (15) . Despite lysosomal DNA accumulation in Dnase2a −/− mice, the lysosomal DNA sensor TLR9 is probably not activated.
Moreover, the TLR9 response in Dnase2a −/− B cells is impaired (16) . These results suggest that TLR9 responses require DNase II-mediated DNA digestion in lysosomes.
Consistent with this, Dnase2a −/− conventional dendritic cells (cDCs) show impaired TLR9 responses (17) . Two types of oligodeoxynucleotides (ODNs) are known to induce two contrasting TLR9 responses (18) . CpG-B induces potent B-cell activation and production of pro-inflammatory cytokines in DCs/macrophages, whereas CpG-A induces production of type I IFNs in plasmacytoid dendritic cells (pDCs). CpG-A needs to have a central palindromic region. Although DNase-resistant modification strengthens agonistic activity in CpG-B, the central palindromic region of CpG-A needs to be sensitive to DNase for type I IFN induction. Little was known about the relationship between the DNasesensitive palindromic region and CpG-A activity. Interestingly, Dnase2a −/− cDCs respond to CpG-B but not CpG-A (17) . The central palindromic region in CpG-A forms a loop, which can be cleaved by DNase II. Possible cleaved fragments that are newly synthesized are able to activate Dnase2a −/− cDCs, suggesting that DNase II digests CpG-A into CpG-B-like fragments for TLR9 activation. These results suggest the essential role of DNase II in processing dsDNA into short ssDNA fragments to activate TLR9. Additional molecules are likely to play a role in processing dsDNA into short ssDNA fragments. Further study needs to identify such molecules.
Inflammatory diseases are also caused by the lack of extracellular, circulating DNases such as DNase I and DNase I like 3 (DNase1l3) in humans and mice (19) (20) (21) (22) . Mice lacking DNase1l3 show lupus nephritis in a manner dependent on a TLR signaling adaptor, MyD88, but not STING, strongly suggesting that TLR9 is activated by circulating extracellular DNA. Considering that mutation of DNase I also induce lupuslike diseases in mice and humans, DNase I and DNase1l3 are likely to play non-redundant roles in digesting extracellular DNA to prevent activation of TLR9.
dsRNA sensing by TLR3
The structure of TLR3 complexed with dsRNA has been reported (23, 24) . TLR3 interacts with dsRNA at two opposite ends of the horseshoe ring of the TLR3 extracellular domain. To form a liganded TLR3 dimer, the length of dsRNA needs to be longer than the width of the TLR3 dimer. This suggests that TLR3 senses dsRNA longer than 40 bp as a virus code. TLR3 also responds to self-derived non-coding RNA released from the cells exposed to a variety of stresses, such as U1 RNA (25) . Upon UV exposure in the skin, TLR3 in keratinocytes and leukocytes induces expression of pro-inflammatory cytokines, leading to skin barrier repair. On the other hand, TLR3 in intestinal epithelial cells induces cell death upon radiation, leading to impairment in the barrier function of gut epithelium (26) . These results suggest the role of TLR3 in stress responses.
In humans, TLR3 is indispensable for innate immune defense against herpes simplex virus 1 (HSV-1) (27) . It remains unknown how the dsRNA sensor TLR3 is activated in infection by a DNA virus such as HSV-1. Along this line, it is of note that the cGAS-STING pathway is activated during HSV-1 infection not only by virus-derived dsDNA but also by dsDNA released from damaged mitochondria (28) . It is possible that TLR3 is activated by self-derived non-coding RNAs during HSV-1 infection. TLR3-dependent stress sensing might contribute to innate immune defense against virus infection.
Nucleoside sensing by TLR7 and TLR8
TLR7 is known as a lysosomal ssRNA sensor (1, 2). The reason why TLR7 needs to be localized in lysosomes is revealed by the structure of TLR7 (5), which has shown that TLR7 binds to guanosine (G) and uridine (U)-containing oligoribonucleotides (ORNs) such as UUU (Fig. 1) . Furthermore, TLR7 is synergistically activated by G and ssRNA (29) . These results suggest that TLR7 responds to RNA degradation products rather than the ssRNA fragment itself. As RNAs are degraded in lysosomes (30) , TLR7 needs to be localized in lysosomes to wait for the generation of RNA degradation products.
The binding site for G is located at the dimerization interface. Similarly, TLR8 binds to uridine (U) at the dimerization interface ( Fig. 1) (6) . Small chemical ligands for TLR7 and TLR8 are known to bind to the site for G or U in TLR7 and TLR8, suggesting that the nucleoside-binding sites in TLR7 and TLR8 are primarily responsible for TLR7 and TLR8 activation. Very importantly, TLR7 responds to dG as well as G in the presence of ssRNA, indicating that TLR7 is activated by degradation products of both DNA and RNA (29) . Furthermore, TLR8 is reported to be activated by oligoDNA (31) , raising a question about whether TLR7 and TLR8 specifically respond to ssRNA. We would like to consider TLR7 and TLR8 as nucleoside sensors rather than ssRNA sensors.
Analyses using purified TLR7 and TLR8 have revealed that their binding to G or U requires preceding interaction between TLR7/TLR8 with ORNs. TLR7 and TLR8 respond to GU-rich and AU-rich ORNs (32) . Viral RNAs including influenza virus, human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are likely to be degraded into these ORNs. In addition to virus-derived RNA, retrovirus elements are suggested to be an important source of ORNs in inflammatory disease states (33) . A well-known autoantigen Ro60 binds to retrovirus element Alu RNA, which is suggested to act on TLR7. The immune complex consisting of Ro60 is likely to contain Alu RNA. After internalization of the immune complex by endocytosis via the B-cell antigen-receptor (BCR) or Fc receptors (FcRs), Alu RNA can act on TLR7, leading to production of auto-antibodies and cytokines such as type I IFNs by B cells and DCs/macrophages, respectively.
Even in the homeostatic state, TLR7 responds to cell corpses (34) . TLR7 is expressed in patrolling monocytes, which play a critical role in homeostatic clearing of endothelial cells. TLR7 activation in patrolling monocytes is required for neutrophil recruitment and subsequent clearance of endothelial cells. The ligand in this situation has not been identified. A variety of ORNs of endogenous and exogenous origins are likely to act on TLR7 in a variety of situations ranging from steady to disease states.
TLR processing as a mechanism enabling TLR dimerization
Lysosomal degradation of DNA and RNA is a requirement for NA sensing by TLRs in lysosomes. Another reason for NA-sensing TLRs to reside in endosomes and lysosomes is the proteolysis of themselves. The extracellular LRRs are proteolytically cleaved in endosomes and lysosomes (35, 36) . Mouse TLR3, TLR7 and TLR9 are proteolytically cleaved at 343S, 461E/462A and 461T/467F, respectively (37-39), separating LRRs into two clusters: LRR1-11 and LRR12-22 in TLR3 and LRR1-14 and 15-26 in TLR7 and TLR9. Although initial studies suggest that TLRs are cleaved into truncated forms to respond to NAs (35, 36, 40) , the N-terminal portions
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are not cleaved off but remain associated with the C-terminal fragments (37, 38) . In the case of TLR7, the N-terminal portion was covalently linked with the C-terminal fragment with a disulfide bond (39, 41) .
The structures of TLR3, TLR7 and TLR9 reveal the essential role of the N-terminal cleaved fragments in interaction with NAs (4, 5, 7, 23) , raising a question about the role of the proteolysis in TLR responses. The cleavage sites are located in non-LRR loop linking N-terminal and C-terminal LRR clusters. The structures of TLR8 and TLR9 and biochemical analyses of their purified proteins suggest that the uncleaved loops cross-over the dimerization interface of TLR8 and TLR9, and thereby inhibit their dimerization but not their interaction with ligands (7, 42) . Therefore, the cleavage of the extracellular LRRs in TLR7, TLR8 and TLR9 is likely to enable liganddependent dimerization.
Endosomal TLRs in the endoplasmic reticulum (ER) are cleaved only after trafficking to endosomes/lysosomes, preventing unnecessary activation of NA-sensing TLRs in the ER and the Golgi apparatus. Endogenous TLRs in the steady state are localized in endosomes/lysosomes and already cleaved in innate immune cells (17, 37, 38, 43) . Therefore, the role of proteolytic cleavage of TLRs is likely to make TLRs ready in lysosomes in the steady state rather than upon ligand activation.
TLR trafficking as a mechanism linking cell adhesion and type I IFNs
NA-sensing TLRs are reported to be localized in the ER and move to endosomes/lysosomes upon ligand stimulation. This conclusion is based on the results studying the subcellular distribution of over-expressed and epitope-tagged TLRs, not endogenous TLRs. We have established monoclonal antibodies (mAbs) to TLR7 and TLR9, and studied the subcellular distribution of endogenous TLR7 and TLR9 in DCs. In contrast to previous studies using over-expressed TLRs, TLR7 and TLR9 are detected in endosomes/lysosomes rather than the ER in bone marrow-derived pDCs, cDCs and macrophages (BM-pDCs, BM-cDCs and BM-MCs) (38, 44, 45) . Of course, the activation status of DCs and macrophages may be different between the in vitro differentiated state and the in vivo steady state. Ligand-dependent trafficking of TLR7 and TLR9 from the ER to endosomal compartments in vivo remains unclarified.
Ligand-dependent TLR trafficking is observed in the endosome/lysosome compartments and has been shown to play a critical role in balancing the downstream signaling pathways. Because NA-sensing TLRs are localized in endosomes and lysosomes, TLR trafficking depends on movement of endosomes and lysosomes. Trafficking of endosomes and lysosomes is controlled by small GTPases such as ADP ribosylation factor like GTPase 8b (Arl8b) and the Ras-related protein 7a (Rab7a) (46) (47) (48) . Arlb8 is required for anterograde lysosomal trafficking from perinuclear regions to peripheral regions, whereas Rab7a controls both anterograde and retrograde trafficking between perinuclear and peripheral regions. These small GTPases are required for the link between endosomes/lysosomes and microtubules.
In BM-pDCs, TLR7, not TLR9, is co-localized and associated with Arl8b (44). Arl8b-deficient, Arl8b gt/gt BM-pDCs show impaired TLR7 trafficking. Salmonella-induced filaments A and kinesin-interacting protein (SKIP) encoded in the Pleckstrin homology domain-containing family M member 2 (Plekhm2) gene is a downstream effector linking Arl8b with kinesin 1. Plekhm −/− BM-pDCs were also impaired in TLR7 trafficking, demonstrating that the Arl8b-SKIP axis links TLR7-containing lysosomes with microtubules through kinesin 1. The role of lysosomal trafficking in TLR7 responses is revealed by studying TLR7 responses in Arl8b gt/gt and Plekhm2 −/− pDCs. Arl8b gt/gt and Plekhm2 −/− BM-pDCs were impaired in type I IFN production, but not pro-inflammatory cytokine production, strongly suggesting that TLR7 trafficking to the cell periphery is linked with production of type I IFNs (Fig. 2) . Interestingly, TLR9 responses were not altered in Arl8b gt/gt and Plekhm2 −/− BM-pDCs, which is consistent with a previous report showing that trafficking of TLR7 and TLR9 is differently regulated (49) .
TLR9 trafficking from the ER to endolysosomes is dependent on adaptor protein-2 (AP-2), a cargo protein mediating vesicular trafficking (49), whereas AP-3 mediates TLR9 movement from late endosomes to lysosome-related organella (50) . AP-3 is required for production of type I IFNs but not pro-inflammatory cytokines. These results suggest that AP-3-dependent TLR9 trafficking enables production of type I IFNs. Although AP-3 is also required for TLR7-dependent production of type I IFNs in pDCs, AP-3 co-localization with TLR7 is decreased with ligand stimulation (44), while AP-3 co-localization with TLR9 increases upon ligand stimulation (44, 50) . The role of AP-3 in production of type I IFNs by TLR7 is unlikely to mediate TLR7 trafficking from perinuclear to peripheral lysosomes.
TLR7, but not TLR9, is associated with Arl8b. TLR7 trafficking is dependent on Arl8b and Plekhm2. In contrast, TLR9 trafficking requires AP-2 and AP-3. These results strongly suggest that TLR7 and TLR9 differently traffic in endosomes and lysosomes. Given that both TLR7 and TLR9 are localized in endosomes and lysosomes, TLR7-containing lysosomes are likely to be distinct from TLR9-containing lysosomes. TLR7-containing lysosomes can be considered as Arl8b-positive lysosomes. Future studies need to identify small GTPases responsible for TLR9 trafficking. It will be interesting to understand why TLR7 and TLR9 need to separately traffic in BM-pDCs.
Ligand activation induces production of pro-inflammatory cytokines and type I IFNs, which are distinct from each other in their requirements for signaling molecules. Whereas MyD88, interleukin-1 receptor-associated kinase 4 (IRAK4) and TNF receptor-associated factor 6 (TRAF6) are required for both pro-inflammatory cytokines and type I IFNs, IRAK1, TRAF3, inhibitor if IκB kinase α (IKKα), IRF7 and mTORC1 (mammalian target of rapamycin complex 1) are additionally required for IFN-α induction in pDCs (51) (52) (53) (54) . Given that TLR trafficking enables production of type I IFNs, recruitment of type I IFN signaling molecules may depend on TLR trafficking. Consistent with this, AP-3 facilitates interaction between the signaling molecules TRAF3 and IRF7 in TLR9 responses (50) . In BM-pDCs, TRAF3 is constitutively associated with IKKα and mTORC1. TLR7 activation induces association between TRAF6 and TRAF3 in a manner dependent on Arl8b, suggesting that TLR7 trafficking enables recruitment of type I IFN signaling molecules. These signaling molecules might be located in the cell periphery, to which TLR7 traffics.
Cytoskeletal change is another requirement for type I IFN production by TLR7. Signaling molecules inducing cytoskeletal changes are therefore required for type I IFN production. TLR7 activation induces microtubule polymerization, which is required for TLR7 trafficking to the cell periphery. Interestingly, the cell adhesion molecules CD11a and CD18 are required for microtubule polymerization, TLR7 trafficking and type I IFN production (44) . MyD88, protein kinase C (PKC), protein kinase D (PKD) and Rap1GTP are required for TLR7-dependent activation of the CD11a/CD18 integrin, which activates integrin-linked kinase (ILK) to induce microtubule polymerization (Fig. 2) . CD11a/CD18 integrin is required for pDC cluster formation, which is formed during viral infection (55) . These results suggest that type I IFN production is preferentially induced in pDC clusters. Consistent with this, type I IFN production by human pDCs shows positive correlation with cell density (56) . Type I IFN production at a high cell density facilitates the paracrine/autocrine action of type I IFN. Very interestingly, type I IFN was detected preferentially at the cell-cell contact (44) , strongly suggesting that type I IFNs behave like a neurotransmitter. The paracrine/autocrine action of type I IFNs is required for full pDC responses (57) , suggesting that pDC clusters provide a platform for pDC response in vivo.
Infectious diseases and NA-sensing TLRs
Because most pathogens are sensed by multiple pathogen sensors including TLRs and non-TLRs, the lack of a single pathogen sensor hardly alters sensitivity to infection. Among human TLRs, only TLR3 is reported to be indispensable for defense against herpesvirus infection. TLR3 and downstream signaling molecules required for TLR3-dependent type I IFN production are indispensable for defense against HSV encephalitis (27, 58) . This is probably due to broad TLR3 expression beyond immune cells. Only TLR3 is expressed in non-hematopoietic cells such as fibroblasts and neurons. Interestingly, peripheral blood monocytes from TLR3-deficient patients are not impaired in type I IFN production in HSV-1 infection (59), because other TLRs such as TLR2 and TLR9 are expressed and activated upon HSV-1 infection (60). In contrast, TLR3-deficient fibroblasts are impaired in type I IFN production during HSV-1 infection. Similarly, HSV sensing in neurons is likely to depend solely on TLR3.
Herpes viruses are also sensed by the cGAS-STING axis, which is expressed in microglia cells in the central nervous system (61) . Type I IFN production by microglia cells up-regulates TLR3 expression in neurons and thereby enables TLR3 activation. Sequential activation of microglia cells and neurons is likely to play an indispensable role in defense against HSV encephalitis.
In mice, TLR3 is known to be indispensable for innate immune defense against poliovirus infection (62, 63) . Although poliovirus infection in TLR3-deficient patients has not been reported, the role of human TLR3 in innate immune defense would not be restricted to HSV-1.
Coordinate activation of NA sensors is also required for the control of endogenous retroviruses. Mice lacking TLR3, TLR7 and TLR9 succumb to lymphoma, which is caused by activation of endogenous retrovirus and resultant insertional mutagenesis in lymphocytes (64) . Among these TLRs, TLR7 plays the most important role in controlling endogenous retroviruses, because increases in mRNA and proteins derived from endogenous retroviruses occur in the absence of TLR7 alone. Consistent with this, exogenous retrovirus infection is effectively controlled by TLR7-dependent antibody responses Nucleic acid-sensing Toll-like receptors 47 (65) . As antibody production is also required for the control of endogenous retroviruses (66), TLR7-dependent antibody production is likely to control both endogenous and exogenous retroviruses. Alu retroelements are likely to be a principal ligand acting on TLR7 in B cells (33) .
Inflammatory diseases driven by NA-sensing TLRs
TLR7 has been implicated in a variety of autoimmune diseases. In the lupus-prone MRL/lpr mouse strain, TLR7 deficiency impairs auto-antibody production to RNA-associated autoantigens (67) . Another lupus-prone mouse strain, BXSBYaa, has an extra-copy of TLR7 (68) (69) (70) . Furthermore, systemic inflammatory lesions are caused by over-expression or mislocalization of TLR7 (68, 71) . Ro60 is a well-known autoantigen, to which auto-antibodies are produced in systemic lupus erythematosus (SLE) and Sjögren syndrome. As Ro60 binds to AluRNA (33) , immune complexes containing Ro60 are likely to contain the TLR7 ligand AluRNA and therefore act on TLR7 after endocytosis through Fc Rs or the BCR in B cells and pDCs, leading to production of auto-antibodies and type I IFNs. It remains unclarified how much TLR7 drives autoimmune responses in human SLE and related autoimmune diseases.
TLR8 protein is expressed in mice but its response is hard to detect. If human TLR8 is expressed in mice, inflammatory legions develop in a variety of organs such as pancreas, salivary glands and joints (72) . It has not been clear whether human TLR8 activation is ligand-dependent or not. As TLR8 senses retroviruses such as HIV (73) , human TLR8 may be activated by mouse endogenous retroviruses.
The pathogenic role of TLR9 has been reported in heart failure and non-alcoholic steatohepatitis (NASH) (74, 75) , where mitochondrial stresses lead to DNA leakage. Mitochondrial DNA activates TLR9 in the heart or the liver. Mitochondrial DNA is detected in the plasma from NASH patients. Liver damage is likely to cause mitochondrial DNA release, which may act on macrophage TLR9 in the liver.
Targeting NA-sensing TLRs to control inflammatory diseases
Although NA-sensing TLRs are activated in endosomes and lysosomes, mAbs to NA-sensing TLRs have revealed that TLR3, TLR7 and TLR9 are expressed on the surface of innate immune cells (37, 38, 43) . Interestingly, our mAbs to TLR7 and TLR9 are able to inhibit their responses in vitro and in vivo (43, 45) . Anti-human and mouse TLR3 are shown to inhibit or enhance TLR3 responses, respectively (37, 76) .
These effects of mAbs on NA-sensing TLR responses are likely to depend on mAb-mediated TLR internalization. Anti-TLR9 mAb is able to inhibit TLR9 responses in macrophages but not pDCs (45) . Anti-TLR9 mAb is internalized after binding to cell surface TLR9 in macrophages but not in pDCs. In contrast, anti-TLR7 mAb is internalized and able to inhibit TLR7 responses in pDCs (43) . If TLR traffic from the cell surface to endolysosomes is one-way, mAbs only react with cell surface TLRs and fail to interact with TLRs in endosomes and lysosomes. However, mAbs to TLR7 and TLR9 are able to inhibit TLR responses almost completely, suggesting that mAbs are able to interact with the TLRs in endosomes and lysosomes. As CD63 continuously shuttles between the plasma membrane and lysosomes (77), TLR7 and TLR9 are likely to shuttle between the plasma membrane and intracellular vesicles particularly in macrophages. Extracellular mAbs may be able to interact with TLR7 and TLR9 in endosomes and lysosomes after their move to the plasma membranes.
Antagonistic mAbs are able to control inflammatory diseases caused by their target TLRs. TLR7-dependent systemic inflammatory lesions are found in mice harboring a D34A mutation in the Unc93b1 gene (71) . These mice suffer from splenomegaly, thrombocytopenia and hepatitis with fibrosis. These changes are ameliorated by anti-TLR7 mAb treatment. Anti-TLR9 mAb is able to rescue mice from lethal hepatitis caused by co-injection of a TLR9 ligand CpG-B and D-(+)-galactosamine (45) , which sensitize hepatocytes to apoptosis induced by TNF-α. These results suggest that antagonistic mAbs are promising tools to control inflammatory diseases driven by TLR7 or TLR9. In addition to mAbs, oligodeoxyribonucleotides are known to control TLR-driven inflammatory diseases such as psoriasis (78) (79) (80) . TLRs are promising targets for therapeutic intervention in a variety of inflammatory diseases.
Conclusion
NAs principally serve as a genetic code but, in the context of infections, they work as a pathogen code (Fig. 3) . Furthermore, NAs play a key role in stress responses, demonstrating another role of NAs as a stress code. Consistent with these multiple roles of NAs in inflammatory responses, NA-sensing TLRs have been implicated in a variety of diseases such as infectious diseases, autoimmune diseases and metabolic diseases. NA-sensing TLRs are likely to contribute to the homeostatic control of a variety of stresses by responding to NAs from dead cells or endogenous retroviruses. Therefore, TLRs are promising targets for therapeutic intervention not only in infectious diseases but also in noninfectious inflammatory diseases.
